SCOUT Shows Challenges Of Cardiovascular Outcomes Trials In Obesity
Executive Summary
Abbott’s SCOUT study of Meridia’s cardiovascular safety shows the design, enrollment and interpretation challenges facing obesity drug developers if FDA were to require CV outcomes studies either pre- or post-approval.
You may also be interested in...
Obesity Drug Developers Aim To Navigate Regulatory Backroads
The major lesson of FDA’s serial rejection of three obesity drugs in a six-month span is that safety is paramount in the weight loss space. That’s agreed. But beyond that, it’s tough to know what to expect, and obesity drug developers face an uncertain regulatory path going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.